Cell line · CVCL_1357
Papers41
1 to 20 of 41
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-myeloma activity of the CXCR4 antagonist WZ811. | J Mol Med (Berl) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Functional Investigation of IGF1R Mutations in Multiple Myeloma. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma. | Cancer Immunol Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. | Leukemia | 2020 | Cellosaurus cites it | PubMed | |
| The LL-100 panel: 100 cell lines for blood cancer studies. | Sci Rep | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. | J Hematol Oncol | 2018 | Cellosaurus cites it | PubMed | |
| Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. | BMC Cancer | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed | |
| Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease. | 2017 | Cellosaurus cites it | Cellosaurus | ||
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1357/papers